Physician profile
Mandy Klass
NPI 1235135260
$4,172.64
in general payments reported to CMS, 2019-2025
13 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $94.50 · 2023: $113 · 2024: $3,848 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,296 · Travel and Lodging: $1,240 · Food and Beverage: $542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,296.00 |
| Travel and Lodging | $1,239.66 |
| Food and Beverage | $542.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,824.11 | 2022-2024 | Krystexxa, Prolia, Evenity |
| Novo Nordisk INC | $65.96 | 2022-2023 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $61.70 | 2024-2025 | Freestyle Libre 3 |
| Abbvie INC. | $43.86 | 2022-2023 | |
| Lilly USA, LLC | $38.92 | 2023-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $23.45 | 2025 | The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $19.07 | 2025 | Breztri |
| Phathom Pharmaceuticals, INC. | $18.63 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $17.66 | 2025 | Rezdiffra |
| Dexcom, INC. | $16.00 | 2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $15.92 | 2022 | |
| Pfizer INC. | $13.72 | 2023 | |
| Glaxosmithkline, LLC. | $13.64 | 2023 | Trelegy Ellipta, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandy Klass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.